|
|
|
|
 |
 |
GlaxoSmithKline Press Releases |
 |
|
|
|
|
8th August, 2007
GSK gives consent under Canada’s Access to Medicines Regime for generic version of HIV/AIDS medicine for use in Rwanda
GSK gives consent under Canada’s Access to Medicines Regime for generic version of HIV/AIDS medicine for use in Rwanda
Not for distribution to US Media
Issued – 8th August 2007, London, UK, Mississauga, ON - As part of its broad commitment to improving access to medicines, GlaxoSmithKline today announced it has given consent through Canada’s Access to Medicines Regime to enable a Canadian company (Apotex) to manufacture a generic fixed dose combination (FDC) antiretroviral (ARV), containing two molecules over which GSK has patent rights (zidovudine and lamivudine) for the treatment of HIV/AIDS in Rwanda ...
|
8th August, 2007
GSK receives decision from FDA on Advair 500/50 for COPD
GSK receives decision from FDA on Advair 500/50 for COPD
Issued — Wednesday 8 August 2007, Research Triangle Park, North Carolina, US
GlaxoSmithKline announced today that the U.S ...
|
3rd August, 2007
GlaxoSmithKline receives new HHS order for H5N1 bulk antigen
GlaxoSmithKline receives new HHS order for H5N1 bulk antigen
First North American clinical trials with GSK’s candidate pre-pandemic flu
vaccine to start
Philadelphia, PA, August 3, 2007—— GlaxoSmithKline (NYSE:GSK), one of
the world’s largest vaccine manufacturers, today announced that HHS has placed
another order to purchase bulk H5N1 antigen for the US national stockpile of
pre-pandemic vaccines ...
|
2nd August, 2007
FDA issues second approvable letter for Trexima™
FDA issues second approvable letter for Trexima™
Issued – Thursday 2 August 2007, London, UK– LSE announcement
GlaxoSmithKline (LSE & NYSE: GSK) and POZEN Inc. (NASDAQ: POZN) today announced that the U.S ...
|
2nd August, 2007
GSK comments on UK Government announcement to renegotiate current Pharmaceutical Pricing and Regulation Scheme agreement
GSK comments on UK Government announcement to renegotiate current Pharmaceutical Pricing and Regulation Scheme agreement
Issued — Thursday 2 August 2007, London, UK - GlaxoSmithKline (GSK) today made the following comment regarding the UK Government’s announcement that it intends to re-negotiate the Pharmaceutical Pricing and Regulation Scheme (PPRS) agreement, which was concluded in 2005 ...
|
30th July, 2007
FDA Advisory Panel votes 22 to 1 for Avandia® to remain available to patients in the US
FDA Advisory Panel votes 22 to 1 for Avandia® to remain available to patients in the US
July 30, 2007 — Philadelphia, PA — GlaxoSmithKline [NYSE: GSK] today welcomed the nearly unanimous recommendation of an U.S ...
|
30th July, 2007
Pharmetrics epidemiology study
Pharmetrics epidemiology study
A study analyzing data on more than 400,000 type 2 diabetes patients in a real-world setting provides strong evidence that Avandia is not associated with the increased risk of heart attack suggested as part of a previously published meta-analysis ...
|
30th July, 2007
GlaxoSmithKline presents Avandia data to FDA
GlaxoSmithKline presents Avandia data to FDA
Philadelphia, PA (July 30, 2007) - The following summarizes GlaxoSmithKline’s [NYSE: GSK] presentation of data on Avandia® (rosiglitazone maleate) to an Advisory Committee of the Food and Drug Administration (FDA) on July 30, 2007 ...
|
27th July, 2007
GlaxoSmithKline and Targacept form alliance in therapeutics for CNS-related disorders
GlaxoSmithKline and Targacept form alliance in therapeutics for CNS-related disorders
Issued – Friday 27 July 2007, London, UK, Philadelphia, PA and Winston Salem, NC
GlaxoSmithKline (GSK) and Targacept, Inc ...
|
27th July, 2007
GlaxoSmithKline statement in diabetes care study thiazolidinediones and heart failure: a teleo-analysis [1]
GlaxoSmithKline statement in diabetes care study thiazolidinediones and heart failure: a teleo-analysis [1]
Issued: Friday 27 July 2007- London, UK - This is an analysis of existing data that has been previously published (online in Diabetes Care, 29 May 2007) and provides no new information on the risk of heart failure associated with the thiazolinediones (TZD) class ...
|
|
|
|
« Previous 10 Next 10 » |
|
|
|
|
